Medicare

LENSAR Reports First Quarter 2024 Results and Provides Business Update

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY® Adaptive Cataract Treatment…

8 months ago

NHI Files Supplemental Proxy

MURFREESBORO, TN / ACCESSWIRE / May 7, 2024 / National Health Investors, Inc. (NYSE:NHI) filed a proxy statement supplement (the…

8 months ago

NHI Announces Second Quarter 2024 Dividend

MURFREESBORO, TN / ACCESSWIRE / May 6, 2024 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay…

8 months ago

Intuity Medical’s POGO Automatic®, the First and Only FDA-Cleared Automatic Blood Glucose Monitor, Now Covered by Medicare Part B

CMS establishes new Medicare coverage codes for the one-step automatic blood glucose monitor, expanding access to millions of seniors living…

8 months ago

iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer…

8 months ago

Dexios Sees Success in Capturing Charges on the Front-end That Would Cause Denials on the Backend

Dexios President - Billie Artcliff: ‘“From reducing coding related denials and direct-to-bill rates of over 85 percent, Maverick's solution has…

8 months ago

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused…

8 months ago

Alignment Healthcare to Present at Two Investor Conferences in May 2024

ORANGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that John Kao, founder and…

8 months ago

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart…

8 months ago

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in…

8 months ago